Conduit Pharma gets Nasdaq deficiency notice after audit committee director resigns

CDT Equity Inc.

Nasdaq notified Conduit on May 28, 2024 that audit committee now has only two independent directors.
Non-compliance triggered by resignation of director Jennifer McNealey from Board and committees.
Cure period runs until earlier of next annual meeting or May 13, 2025; no immediate delisting.
Company intends to regain compliance by adding a third independent audit committee member.
Common stock (CDT) and warrants (CDTTW) continue trading on Nasdaq during cure period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.